Exploring Anticancer Potential of Amomum Flavonoids Targeting ALK: DFT, Docking, and Molecular Dynamics Study
International Journal of Health, Medicine, and Sports · 10.06.2026 · 4 (3)
DOI: 10.46336/ijhms.v4i3.342 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Health, Medicine, and Sports, online erschienen am 10.06.2026. Verfasst von Deden Indra Dinata und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lung cancer remains the leading cause of cancer-related mortality worldwide, with an estimated 2.5 million new cases and 1.8 million deaths reported in 2022. Non-small cell lung cancer (NSCLC) accounts for 80–85% of all cases, among which adenocarcinoma is the predominant histological subtype. Anaplastic lymphoma kinase (ALK) gene rearrangements occur in approximately 3–5% of lung adenocarcinoma patients, conferring sensitivity to ALK-targeted therapies. Flavonoids, key secondary metabolites in the genus Amomum, have exhibited promising anticancer properties. This in silico study systematically investigated the binding interactions, affinity, and dynamic stability of flavonoid derivatives derived from various Amomum species in complex with the ALK receptor. Molecular docking revealed that compound c21 exhibits superior binding affinity, with a predicted free energy of –10.10 kcal/mol and an inhibition constant (Kᵢ) of 39.7 nM, outperforming the native ligand. Notably, c21 forms hydrogen bonds with Met1199 and Asp1270 and engages in hydrophobic contacts with Leu1122, Leu1256, Pro1260, Phe1207, and Lys1150 within the ALK binding site. Subsequent molecular dynamics simulations of ALK–c20, ALK–c21, and ALK–c22 complexes highlighted compound c22 as the most dynamically stable ligand: its RMSD and RMSF profiles show minimal fluctuations in key residues, and its estimated binding free energy (∆G) closely approximates that of the endogenous ligand. Taken together, these findings suggest that Amomum-derived flavonoids—particularly c21 and especially c22—merit further investigation as potential therapeutic agents targeting ALK-positive NSCLC.
Zitieren
APA
Dinata, D. I., Junjunan, R. A., & Muttaqin, F. Z. (2026). Exploring Anticancer Potential of Amomum Flavonoids Targeting ALK: DFT, Docking, and Molecular Dynamics Study. International Journal of Health, Medicine, and Sports, 4(3). https://doi.org/10.46336/ijhms.v4i3.342
Vancouver
Dinata DI, Junjunan RA, Muttaqin FZ. Exploring Anticancer Potential of Amomum Flavonoids Targeting ALK: DFT, Docking, and Molecular Dynamics Study. International Journal of Health, Medicine, and Sports. 2026;4(3). doi:10.46336/ijhms.v4i3.342
BibTeX
@article{Dinata2026,
author = {Dinata, Deden Indra and Junjunan, Repita Anis and Muttaqin, Fauzan Zein},
title = {Exploring Anticancer Potential of Amomum Flavonoids Targeting ALK: DFT, Docking, and Molecular Dynamics Study},
journal = {International Journal of Health, Medicine, and Sports},
year = {2026},
volume = {4},
number = {3},
doi = {10.46336/ijhms.v4i3.342}
}
EUVIMED